Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab

The TCC capacity may represent a novel and easy to perform parameter to determine level of complement inhibition in patients treated with eculizumab, especially because it identifies the residual capacity of inhibition at pathophysiological stages.